Home› Situations› ALNY — Gap to peers
Situation · 2026-06-12

ALNY — Gap to peers

Premium on Momentum, Not on Stability

Updated 2026-06-12 · Ref: Biotechnology
Key metrics — 2026-06-12
Peer score
63
Quality pct
71
Valuation pct
34
52w drawdown
-42.4%
21d vs sector
-2.0%
Peer group
Biotechnology
Situation summary

ALNY trades as a rare-disease growth story, not a defensive pharma. The market reads 96.4% revenue growth as momentum, but 46.2% volatility means any slip hits hard. Even a single weak quarter can spark a sharp selloff. Too risky for a premium biotech.

Published by AssetNext · 2026-06-13

All companies with this signal today

View full list: Gap to peers →

Related pages for ALNY
Full peer analysis for Alnylam Pharmaceuticals, Inc. →Similar companies to ALNYALNY peersAll ALNY comparisonsNasdaq-100 context
Signal history — last 30 days
Date Signal Peer score Drawdown 21d vs sector
2026-06-08 Gap to peers 62 -40.5% +1.0%

See ALNY's full peer analysis

Break down ALNY's structural position across all peer dimensions with the interactive app.

Open ALNY in AssetNext →